Researcher
Lucas Van Aelst
- Disciplines:Cardiac and vascular medicine
Affiliations
- Department of Cardiovascular Sciences (Department)
Member
From1 Oct 2018 → 20 Dec 2018 - Cardiology (Division)
Member
From1 Mar 2015 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Jan 2012 → 31 Dec 2014
Projects
1 - 4 of 4
- To cure is to live: reducing cardiac impact of modern breast cancer radiotherapy.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failureFrom1 Oct 2023 → TodayFunding: Horizon Europe - Health
- Preclinical and clinical assessment of the beneficial effects of hepcidin, a pivotal endogenous regulator of iron metabolism, on anthracycline-induced cardiotoxicity.From1 Apr 2022 → 20 Dec 2023Funding: Other federal public and semi-governmental institutions
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 65
- Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy.(2024)
Authors: Johanna Jacobs, Hans Wildiers, Rik Willems, Jens-Uwe Voigt, Lucas Van Aelst
Pages: 560 - 566 - Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions.(2024)
Authors: Lorenz Van der Linden, Lucas Van Aelst
Pages: 395 - 396 - Artificial Intelligence ECG as a Novel Method to Detect Cardiotoxicity After Anthracyclines(2023)
Authors: Johanna Jacobs, Rik Willems, Lucas Van Aelst
- Tools to differentiate between Filamin C and Titin truncating variant carriers: value of MRI(2023)
Authors: Johanna Jacobs, Lucas Van Aelst, Jeroen Breckpot, Ward Heggermont, Rik Willems, Jan Bogaert, Tomas Robyns
Pages: 1323 - 1332 - Urinary proteomics signature of malignancy post heart transplantation is associated with mortality risk(2023)
Authors: Lucas Van Aelst
- Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?(2023)
Authors: Laura Hellemans, Jos Tournoy, Christophe Vandenbriele, Lucas Van Aelst, Lorenz Van der Linden
Pages: 367 - 369 - Induced pluripotent stem cell-derived cardiac myocytes to assess anthracycline cardiotoxicity(2023)
Authors: Johanna Jacobs, Robin Duelen, Ward Heggermont, Maurilio Sampaolesi, Heidi Segers, Lucas Van Aelst
- Prediction of coronary artery disease using urinary proteomics(2023)
Authors: Dongmei Wei, Lucas Van Aelst, Thomas Vanassche, Peter Verhamme, Zhenyu Zhang
Pages: 1537 - 1546 - Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis(2023)
Authors: Lorenz Van der Linden, Thomas Vanassche, Lucas Van Aelst, Peter Verhamme
Pages: 2369 - 2376 - Guideline-Directed Medical Therapies for Heart Failure with a Reduced Ejection Fraction in Older Adults: A Narrative Review on Efficacy, Safety and Timeliness(2023)
Authors: Lorenz Van der Linden, Jos Tournoy, Christophe Vandenbriele, Lucas Van Aelst
Pages: 691 - 702